Mineralys Therapeutics Stock In Shambles: Down -25% With 6-Day Losing Streak
Mineralys Therapeutics (MLYS) – a biopharmaceutical company developing aldosterone-targeting medicines – hit a 6-day losing streak, with cumulative losses over this period amounting to -25%. The company’s market cap has crashed by about $650 Mil over the last 6 days and currently stands at $2.0 Bil.
Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.
But here is the interesting part. You are reading about this -25% move after it happened. The market has already priced in the news. To manage individual stock risk before the headlines, you need predictive signals, not notifications. High Quality Portfolio has a risk model designed to manage stock-specific drawdowns better.
Returns vs S&P 500
- Can CRWD Stock Deliver If The AI Boom Stalls?
- The Multi-Year Backlog Seagate Stock Skeptics Are Ignoring
- Is NVIDIA Stock’s New CPU Story Big Enough to Cover Its China Silence?
- What Is Google Hiding Behind Its AI Silence?
- Oracle Just Showed Wall Street the AI Boom, Then Handed It The Bill
- Beyond the Sticker Price: What a Patient Investor Really Pays for Broadcom Stock
The following table summarizes the return for MLYS stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | MLYS | S&P 500 |
|---|---|---|
| 1D | -5.4% | -2.6% |
| 6D (Current Streak) | -24.9% | -2.4% |
| 1M (21D) | -21.3% | 0.3% |
| 3M (63D) | -10.9% | 9.6% |
| YTD 2026 | -34.7% | 7.9% |
| 2025 | 194.8% | 16.4% |
| 2024 | 43.1% | 23.3% |
| 2023 | 24.2% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 74 S&P constituents with 3 days or more of consecutive gains and 42 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 41 | 22 |
| 4D | 26 | 17 |
| 5D | 7 | 3 |
| 6D | 0 | 0 |
| 7D or more | 0 | 0 |
| Total >=3 D | 74 | 42 |
Key Financials for Mineralys Therapeutics (MLYS)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-192.4 Mil | $-170.6 Mil |
| Net Income | $-177.8 Mil | $-154.7 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-38.3 Mil | $-45.3 Mil |
| Net Income | $-32.2 Mil | $-39.3 Mil |
The losing streak MLYS stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.